Skip to main content
OpenTrials
Completed

NCT Number: NCT01049516

Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) Among Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) Personnel

The purpose of this study is 1) to evaluate whether massing 10 PE sessions in 2 weeks (massed trials; M-PE) is more efficacious than Minimal Contact control (MCC); 2) whether the massed sessions format retains the efficacy of treatment compared to 10 PE sessions spaced over 8 weeks (spaced trials; S-PE), and 3) to evaluate for the first time the efficacy of the 10 PE sessions delivered in 8 weeks in an active duty population by comparing it to an active comparison condition, Present-Centered Therapy (PCT).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Center for the Treatment and Study of Anxiety, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Loading trial locations.

About this study

The purpose of this study is to improve the efficiency of treatment for post-traumatic stress disorder (PTSD) with prolonged exposure (PE), an efficacious treatment for PTSD typically administered in once- or twice-weekly sessions. We will evaluate whether massing 10 PE sessions in 2 weeks (massed trials; M-PE) is more efficacious than Minimal Contact control (MCC); 2) whether the massed sessions format retains the efficacy of treatment compared to 10 PE sessions spaced over 8 weeks (spaced trials; S-PE), and 3) will evaluate for the first time the efficacy of the 10 PE sessions delivered in 8 weeks in an active duty population by comparing it to an active comparison condition, Present-Centered Therapy (PCT). Randomization was initially set at 3:11:11:11 for MCC:M-PE:S-PE:PCT. Due to the urgent need for data to inform military clinical practice, enrollment in MCC was accelerated by changing the ratio to 1:1:1:1 in order to report the comparison between M-PE and MCC. When 30 participants were enrolled in MCC, randomization resumed to approximately 3:11:11:11. Prolonged Exposure (PE; Foa, Hembree, & Rothbaum, 2007; Foa & Rothbaum, 1998) was developed by the PI, Edna Foa, and colleagues in the Center for the Treatment & Study of Anxiety (CTSA), University of Pennsylvania. It has been found quite efficacious in reducing PTSD and related psychopathology with various types of trauma in PTSD centers around the world. Furthermore, PE has been identified in the joint VA-Department of Defense Clinical Practice Guideline for PTSD (VA-DoD Clinical Practice Guideline Working Group, 2003) as "strongly recommended" for use with veterans with PTSD, based on the strong empirical support for PE.

This study is part of the South Texas Research Organizational Network Guiding Studies on Trauma and Resilience (STRONG STAR) (Consortium Director: Alan L. Peterson, Ph.D., ABPP, Professor, Behavioral Wellness Center for Clinical Trials, Department of Psychiatry-Mail Code 7792, University of Texas Health Science Center at San Antonio (UTHSCSA), 7703 Floyd Curl Drive, San Antonio, TX 78229-3900). Dr. Edna Foa is the overall PI of the study, and the on-site PI is COL Jeffrey Yarvis, Ph.D.,Chief, Soldier Behavioral Health/Outpatient Psychiatry, Carl R. Darnall Army Medical Center, 36000 Darnall Loop, Fort Hood, TX, 76544. The study will be conducted at Fort Hood, Texas.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult male and female active-duty OIF/OEF military personnel and recently separated OIF/OEF veterans ages 18-65 seeking treatment for PTSD
  • Diagnosis of PTSD determined by a clinician-administered Posttraumatic Stress Scale (PSS-I).

Exclusion criteria

  • Current bipolar disorder or other psychotic disorder (as determined by the evaluator conducting the patient interview and medical record review)
  • Current alcohol dependence (as determined by the AUDIT)
  • Evidence of a moderate or severe traumatic brain injury (as determined by the inability to comprehend the baseline screening questionnaires)
  • Current suicidal ideation severe enough to warrant immediate attention (as determined by the Scale for Suicidal Ideation)
  • Other psychiatric disorders severe enough to warrant designation as the primary disorder

Treatment and study plan

Prolonged Exposure Therapy - Massed

Behavioral

10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.

Other names: Massed-PE

Prolonged Exposure Therapy - Spaced

Behavioral

10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.

Other names: Spaced-PE

Minimal contact control

Behavioral

Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.

Other names: Wait List

Present-Centered Therapy

Behavioral

10 75-90 minute psychotherapy sessions, focused on identifying and solving day-to-day problems as they are brought up by the participants

Primary outcomes

  1. Change in PTSD Symptom Scale, Interview Version (PSS-I) following treatment

    Time frame: Baseline to 6-month follow-up (approximately 34 weeks for Spaced PE and PCT, 26 weeks for Massed PE

    Affect of treatment on this measure of PTSD symptomology

Secondary outcomes

  1. PTSD Checklist-Stressor-specific version (PCL-S)

    Time frame: Baseline to Post-treatment (approximately 10 weeks for Spaced PE and PCT, 2 weeks for Massed PE)

    Affect of treatment on a PTSD Assessment of stress

  2. PTSD Checklist-Stressor-specific version (PCL-S)

    Time frame: Post-treatment to 2-week follow-up

    Changes in PTSD stress symptomology upon commencement of treatment

  3. PTSD Checklist-Stressor-specific version (PCL-S)

    Time frame: 2-week follow-up to 12-week follow-up

    Changes in PTSD stress symptomology upon commencement of treatment

  4. PTSD Checklist-Stressor-specific version (PCL-S)

    Time frame: 12-week follow-up to 6-month follow-up

    Changes in PTSD stress symptomology upon commencement of treatment

  5. Changes in PTSD diagnosis using PTSD Symptom Scale, Interview Version (PSS-I) over course of treatment

    Time frame: Baseline to Post-treatment (approximately 10 weeks for Spaced PE and PCT, 2 weeks for Massed PE)

    PTSD Assessment

  6. Changes in PTSD diagnosis using PTSD Symptom Scale, Interview Version (PSS-I) following treatment

    Time frame: Post-treatment to 2-week follow-up

    PTSD Assessment

  7. Changes in PTSD diagnosis using PTSD Symptom Scale, Interview Version (PSS-I) following treatment

    Time frame: 2-week follow-up to 12-week follow-up

    PTSD Assessment

  8. Changes in PTSD diagnosis using PTSD Symptom Scale, Interview Version (PSS-I) following treatment

    Time frame: 12-week follow-up to 6-month follow-up

    PTSD Assessment

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Collaborators

  • The University of Texas Health Science Center at San Antonio
  • U.S. Army Medical Research and Development Command

Registry information

Official study title

Prolonged Exposure for PTSD Among OIF/OEF Personnel: Massed vs. Spaced Trials

Acronym: STRONG STAR

Important dates

Study start
2010
Primary completion
2018
Study completion
2018
First posted
Jan 14, 2010
Registry last updated
Nov 27, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.